New advances in the management of a long-neglected disease

Clinical Infectious Diseases

Volumn 49, Issue 11, 2009, Pages 1685-1687

  Urbina, Julio A ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; GAMMA INTERFERON; INTERLEUKIN 2;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; CHAGAS DISEASE; CHILD; CLINICAL ARTICLE; CONGENITAL INFECTION; CYTOKINE RELEASE; DISEASE TRANSMISSION; DRUG EFFICACY; ENDEMIC DISEASE; HUMAN; IMMUNE RESPONSE; INFANT; NONHUMAN; NOTE; PARASITE IDENTIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; T LYMPHOCYTE; TREATMENT RESPONSE; TROPICAL DISEASE; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS; ZOONOSIS;

ADULT; ANIMALS; BOLIVIA; CD8-POSITIVE T-LYMPHOCYTES; CHAGAS DISEASE; DNA, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERFERON-GAMMA; INTERLEUKIN-2; MIDDLE AGED; NITROIMIDAZOLES; POLYMERASE CHAIN REACTION; PREGNANCY; T-LYMPHOCYTES; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI; YOUNG ADULT;

EID: 72849128723     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648073     Document Type: Note

References (32)

1. Bern C, Verastegui M, Gilman RH, et al. Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia. Clin Infect Dis 2009; 49: 1667-1674 (in this issue).
2. Laucella SA, Pérez Mazliah D, Bertocchi C, et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 2009; 49:1675-1684 (in this issue).
3. Aufderheide AC, Salo W, Madden M, et al. A 9000-year record of Chagas disease. Proc Natl Acad Sci U S A 2004; 101:2034-2039
4. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical disease of Latin American and the Caribbean: a review of disease burden and distribution and a roadmap for contron and elimination. PLoS Negl Trop Dis 2008; 2:e300.
5. Schofield CJ, Jannin J, Salvatella R. The future of Chagas disease control. Trends Parasitol 2006; 22:583-588
6. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gurtler RE. The challenges of Chagas Disease-grim outlook or glimmer of hope. PLoS Med 2007; 4:e332.
7. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007; 298:2171-2181 (Pubitemid 350106656) (Pubitemid 350106656)
8. Diaz JH. Chagas disease in the United States: a cause for concern in Louisiana? J La State Med Soc 2007; 159:21-3, 25-29
9. Piron M, Verges M, Munoz J, et al. Seroprevalence of Trypanosoma cruzi infection in atrisk blood donors in Catalonia (Spain). Transfusion 2008; 48:1862-1868.
10. Gascon J, Albajar P, Canas E, et al. Diagnosis, management and treatment of chronic Chagas heart disease in areas where Trypanosoma cruzi infection is not endemic. Rev EspCardiol 2007; 60:285-293 (Pubitemid 46691793) (Pubitemid 46691793)
11. Brener Z, Gazzinelli RT. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas disease. Int Arch Allergy Immunol 1997; 114:103-110 (Pubitemid 27397063)
12. Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas disease. Heart 2009; 95:524-534
13. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007; 115:1109-1123 (Pubitemid 46679556) (Pubitemid 46679556)
14. + T cells in chronic Chagas disease patients. Int Immunol 2006; 18:465-471
15. Reithinger R, Tarleton RL, Urbina JA, Kitron U, Gurtler RE. Eliminating Chagas disease: challenges and a roadmap. BMJ 2009; 338: b1283.
16. Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz 2002; 97: 603-612
17. Ribeiro I, Sevcsik AM, Alves F, et al. New, improved treatments for chagas disease: from the R&D pipeline to the patients. PLoS Negl Trop Dis 2009; 3:e484.
18. Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances, Trends Parasitol 2003; 19:495-501. (Pubitemid 37329658) (Pubitemid 37329658)
19. Schijman AG, Altcheh J, Burgos JM, et al. Aetiological treatment of congenital Chagas disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother 2003; 52:441-449 (Pubitemid 37120724) (Pubitemid 37120724)
20. Virreira M, Torrico F, Truyens C, et al. Comparison of PCR methods for the diagnosis of congenital Trypanosoma cruzi infection. Rev Soc Bras Med Trop 2005; 38(Suppl 2):65-67
21. Cançado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 2002; 44:29-37.
22. Pinto Dias JC. The treatment of Chagas disease (South American trypanosomiasis). Ann Intern Med 2006; 144:772-774 (Pubitemid 46780638)
23. Gomes YM, Lorena VM, Luquetti AO. Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow up studies?Mem Inst Oswaldo Cruz 2009; 104:115-121
24. Cooley G, Etheridge RD, Boehlke C, et al. High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis 2008; 2:e316.
25. + T central memory response in chronic Chagas disease. Nat Med 2008; 14:542-550
26. Fernandes CD, Tiecher FM, Balbinot MM, et al. Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem Inst Oswaldo Cruz 2009; 104:27-32.
27. Anez N, Carrasco H, Parada H, et al. Myocardial parasite persistence in chronic chagasic patients.AmJ Trop Med Hyg 1999; 60:726-732
28. Britto C, Silveira C, Cardoso MA, et al. Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction. Mem Inst Oswaldo Cruz 2001; 96:823-826 (Pubitemid 33639948)
29. Braga MS, Lauria-Pires L, Arganaraz ER, Nascimento RJ, Teixeira AR. Persistent infections in chronic Chagas disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop Sao Paulo 2000; 42:157-161 (Pubitemid 32229947) (Pubitemid 32229947)
30. Benvenuti LA, Roggerio A, Freitas HF,Mansur AJ, Fiorelli A, Higuchi ML. Chronic American trypanosomiasis: parasite persistence in endomyocardial biopsies is associated with highgrade myocarditis. Ann Trop Med Parasitol 2008; 102:481-487
31. Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg 1987; 81:755-759 (Pubitemid 18070985) (Pubitemid 18070985)
32. Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins sans Frontieres. PLoS Negl Trop Dis 2009; 3:e488.